Could Viking Therapeutics Become the Next Eli Lilly?

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years.Amid this estimated $100 billion opportunity, much smaller upstart Viking Therapeutics (NASDAQ: VKTX) has emerged with a promising clinical pipeline, aiming to capture a share of the weight loss and metabolic disease market with its novel dual-agonist approach. Despite a long road ahead for this clinical-stage biotech, recent data suggesting that its VK2735 candidate could rival and even outperform the leading therapies highlights the significant potential of this exciting small-cap stock.Could Viking Therapeutics be the next Eli Lilly? Here's what you need to know.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool